AONN+ Conference Abstracts
Julie Prettyman, RN, BSN, CCRC, John A. McLane, PhD, Stuart N. Atkinson, MB, ChB, Allison Tyler, RN, BSN, OCN, CCRP, Deborah M. Boldt-Houle, PhD
In prostate cancer therapy, achieving and maintaining effective testosterone (T) suppression to the level attained with surgical castration is the cornerstone of androgen deprivation therapy (ADT).
Palbociclib is the first-in-class cyclin-dependent kinase 4/6 inhibitor approved in the United States in combination with an aromatase inhibitor (AI) or fulvestrant for treating patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced or metastatic breast cancer (mBC) as initial or later-line endocrine therapy. More than 80,000 patients have been treated in the United States with palbociclib since its approval in February 2015, but data on real-world palbociclib utilization are limited.
Edythe M. Greenberg, PhD, RN, FNP-BC, Jillian Settlemire, RN, Sandra Dai, PhD, MS, James P. Dean, MD, PhD, Tony Lin, PharmD, Steven Coutre, MD, Jan Berger, MD, PhD
Ibrutinib is a first-in-class, once-daily inhibitor of BTK approved in the United States for treatment of CLL/SLL. RESONATE-2 is a phase 3 study comparing first-line ibrutinib versus chlorambucil in patients with CLL/SLL. Primary results (median follow-up, 18.4 months) demonstrated ibrutinib reduced risk of progressive disease (PD) or death by 84% (Burger, 2015).
Heidi Eve-Cahoon, MSN, RN, CNP, CBCN, Sharon Lieb Inzetta, RN, MS, CBCN, CN-BN, ONN-CG, Melanie Lynch, MD, FACS, Laura Musarra, BS, MBA
Today there are ever-increasing challenges surrounding breast cancer care. The ongoing disparities in delivering cancer care continue to impact our nation as a whole, and, more importantly, for both patients and providers in our local communities.
Nora J. Barrett, BSN, RN, OCN, ONN-CG, Kristi C. Garrison, MS, CHES, CHW, OPN-CG, Stacey L. Webb, MPA-HCA, BSN, RN, ONN-CG
Currently, pancreatic cancer (PC) is the fourth leading cause of cancer mortality in the United States. However, with the lack of early detection tests and treatment options, it is estimated that PC may move to the second leading cause of cancer death in the United States by 2020 or even earlier.
The tumor board, or multidisciplinary cancer conference (MCC), is the foundation of high-value multidisciplinary oncology care through coordinating teams of specialists.
According to Morgan, “Lung Cancer is the leading cause of cancer-related death in the United States, claiming more lives than colon, breast, and prostate cancer combined.”
The multidisciplinary cancer conference (MCC) plays an integral role in optimizing patient outcomes in today’s increasingly complex world of cancer care.
Accessing chimeric antigen receptor (CAR) T-cell clinical trials for relapsed and refractory B-cell acute lymphoblastic leukemia (ALL) is challenging for pediatric patients who have experienced a relapse of B-cell ALL or have been refractory to standard therapy.
The Johns Hopkins Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Sibley Memorial Hospital, performs more than 500 surgeries annually.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512